Table Info

Table 1.

TRAF5 and diseases in mice and humans

Species	Diseases	Phenotypes	References
Human	AS	Enhanced methylation of CpG island of TRAF5 gene promoter and decreased TRAF5 gene expression in PBMCs	[31]
	RA	A SNP mapping upstream of TRAF5 gene and affecting a putative transcription factor binding site	[32]
	Uveitis	SNPs in TRAF5 gene	[33]
	SS	Decreased TRAF5 gene expression in the temporal bulbar conjunctiva	[35]
	SLE	Enhanced TLR7 signaling caused by decreased expression of TRAF5 in B cells (pre-plasma cells)	[36]
	Coronary heart disease	Decreased TRAF5 gene expression in the blood	[21]
	Obesity with a high cardiovascular risk	Decreased TRAF5 gene expression in blood leukocytes and adipocytes	[20]
	NAFLD	Decreased TRAF5 protein expression in the liver	[23]
Mouse	Allergic asthma	Enhanced Th2 responses caused by Traf5-deficiency	[18]
	EAE	Enhanced Th17 responses caused by Traf5-deficiency	[13]
	Wound healing	Increased pDC-mediated wound repair inflammatory responses caused by Traf5-deficiency	[27]
	Atherosclerosis	Enhanced atherosclerosis caused by Traf5-deficiency	[21]
	Diet-induced obesity	Enhanced diet-induced obesity and inflammation in the adipose tissue caused by Traf5-deficiency	[20]
	NAFLD	Enhanced hepatic steatosis caused by Traf5-deficiency	[23]
	Myocardial ischemia-reperfusion injury	Exacerbated inflammation and cell death after a myocardial ischemia-reperfusion injury caused by Traf5-deficiency	[22]

PBMCs: peripheral blood mononuclear cells

Declarations

Acknowledgments

We thank the Life Science Research Center, University of Toyama and the Institute for Animal Experimentation, Tohoku University Graduate School of Medicine for technical support. We thank members of Laboratory of Molecular Cell Biology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, and Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine for their assistance and help. We also thank Michael Croft and Hiroyasu Nakano for Traf5^−/− mice and for their encouragement at the start of the project.

Author contributions

TS and NI: Supervision. TS and MHK: Writing—original draft. TS, NI and MHK: Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

The study was approved by Japan Society for the Promotion of Science KAKENHI [Grants JP15H04640 (T.S.), JP18H02572 (T.S.)]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell. 1994;78:681–92. [DOI] [PubMed]

So T. The immunological significance of tumor necrosis factor receptor-associated factors (TRAFs). Int Immunol. 2022;34:7–20. [DOI] [PubMed]

Gissler MC, Stachon P, Wolf D, Marchini T. The role of tumor necrosis factor associated factors (TRAFs) in vascular inflammation and atherosclerosis. Front Cardiovasc Med. 2022;9:826630. [DOI] [PubMed] [PMC]

Arkee T, Bishop GA. TRAF family molecules in T cells: multiple receptors and functions. J Leukoc Biol. 2020;107:907–15. [DOI] [PubMed] [PMC]

Lalani AI, Zhu S, Gokhale S, Jin J, Xie P. TRAF molecules in inflammation and inflammatory diseases. Curr Pharmacol Rep. 2018;4:64–90. [DOI] [PubMed] [PMC]

So T, Nagashima H, Ishii N. TNF receptor-associated factor (TRAF) signaling network in CD4⁺ T-Lymphocytes. Tohoku J Exp Med. 2015;236:139–54. [DOI] [PubMed]

Xie P. TRAF molecules in cell signaling and in human diseases. J Mol Signal. 2013;8:7. [DOI] [PubMed] [PMC]

Ha H, Han D, Choi Y. TRAF-mediated TNFR-family signaling. Curr Protoc Immunol. 2009;Chapter 11:11.9D.1-11.9D.19. [DOI] [PubMed]

Park HH. Structure of TRAF family: current understanding of receptor recognition. Front Immunol. 2018;9:1999. [DOI] [PubMed] [PMC]

10.

Chung JY, Park YC, Ye H, Wu H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci. 2002;115:679–88. [DOI] [PubMed]

11.

Nakano H, Oshima H, Chung W, Williams-Abbott L, Ware CF, Yagita H, et al. TRAF5, an activator of NF-κB and putative signal transducer for the lymphotoxin-beta receptor. J Biol Chem. 1996;271:14661–4. [DOI] [PubMed]

12.

Ishida TK, Tojo T, Aoki T, Kobayashi N, Ohishi T, Watanabe T, et al. TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci U S A. 1996;93:9437–42. [DOI] [PubMed] [PMC]

13.

Nagashima H, Okuyama Y, Asao A, Kawabe T, Yamaki S, Nakano H, et al. The adaptor TRAF5 limits the differentiation of inflammatory CD4⁺ T cells by antagonizing signaling via the receptor for IL-6. Nat Immunol. 2014;15:449–56. [DOI] [PubMed] [PMC]

14.

Yeh WC, Shahinian A, Speiser D, Kraunus J, Billia F, Wakeham A, et al. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity. 1997;7:715–25. [DOI] [PubMed]

15.

Nguyen LT, Duncan GS, Mirtsos C, Ng M, Speiser DE, Shahinian A, et al. TRAF2 deficiency results in hyperactivity of certain TNFR1 signals and impairment of CD40-mediated responses. Immunity. 1999;11:379–89. [DOI] [PubMed]

16.

Xu Y, Cheng G, Baltimore D. Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity. 1996;5:407–15. [DOI] [PubMed]

17.

Nakano H, Sakon S, Koseki H, Takemori T, Tada K, Matsumoto M, et al. Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation. Proc Natl Acad Sci U S A. 1999;96:9803–8. [DOI] [PubMed] [PMC]

18.

So T, Salek-Ardakani S, Nakano H, Ware CF, Croft M. TNF receptor-associated factor 5 limits the induction of Th2 immune responses. J Immunol. 2004;172:4292–7. [DOI] [PubMed]

19.

Kawahara E, Azuma M, Nagashima H, Omori K, Akiyama S, Fujimori Y, et al. TNF receptor-associated factor 5 limits IL-27 receptor signaling in CD4⁺ T Lymphocytes. J Immunol. 2022;208:642–50. [DOI] [PubMed]

20.

Gissler MC, Anto-Michel N, Pennig J, Scherrer P, Li X, Marchini T, et al. Genetic deficiency of TRAF5 promotes adipose tissue inflammation and aggravates diet-induced obesity in mice. Arterioscler Thromb Vasc Biol. 2021;41:2563–74. [DOI] [PubMed]

21.

Missiou A, Rudolf P, Stachon P, Wolf D, Varo N, Aichele P, et al. TRAF5 deficiency accelerates atherogenesis in mice by increasing inflammatory cell recruitment and foam cell formation. Circ Res. 2010;107:757–66. [DOI] [PubMed]

22.

Xu W, Zhang L, Ma S, Zhang Y, Cai Z, Zhang K, et al. TRAF5 protects against myocardial ischemia reperfusion injury via AKT signaling. Eur J Pharmacol. 2020;878:173092. [DOI] [PubMed]

23.

Gao L, Wang PX, Zhang Y, Yu CJ, Ji Y, Wang X, et al. Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis. J Hepatol. 2016;65:125–36. [DOI] [PubMed]

24.

Sanjo H, Zajonc DM, Braden R, Norris PS, Ware CF. Allosteric regulation of the ubiquitin: NIK and ubiquitin: TRAF3 E3 ligases by the lymphotoxin-beta receptor. J Biol Chem. 2010;285:17148–55. [DOI] [PubMed] [PMC]

25.

Piao JH, Yoshida H, Yeh WC, Doi T, Xue X, Yagita H, et al. TNF receptor-associated factor 2-dependent canonical pathway is crucial for the development of Peyer’s patches. J Immunol. 2007;178:2272–7. [DOI] [PubMed]

26.

Kobayashi S, Shiota Y, Kawabe T, Phung HT, Maruyama T, Owada Y, et al. TRAF5 promotes plasmacytoid dendritic cell development from bone marrow progenitors. Biochem Biophys Res Commun. 2020;521:353–9. [DOI] [PubMed]

27.

Kobayashi S, Sakurai T, So T, Shiota Y, Asao A, Phung HT, et al. TNF receptor-associated factor 5 limits function of plasmacytoid dendritic cells by controlling IFN regulatory factor 5 expression. J Immunol. 2019;203:1447–56. [DOI] [PubMed]

28.

Machiyama T, So T, Okuyama Y, Kobayashi S, Phung HT, Asao A, et al. TNF receptor associated factor 5 controls oncostatin M-mediated lung inflammation. Biochem Biophys Res Commun. 2018;499:544–50. [DOI] [PubMed]

29.

Phung HT, Nagashima H, Kobayashi S, Asano N, Machiyama T, Sakurai T, et al. TRAF5 deficiency ameliorates the severity of dextran sulfate sodium colitis by decreasing TRAF2 expression in nonhematopoietic cells. Immunohorizons. 2020;4:129–39. Erratum in: Immunohorizons. 2020;4:216. [DOI] [PubMed]

30.

Shang J, Li L, Wang X, Pan H, Liu S, He R, et al. Disruption of tumor necrosis factor receptor-associated factor 5 exacerbates murine experimental colitis via regulating T helper cell-mediated inflammation. Mediators Inflamm. 2016;2016:9453745. [DOI] [PubMed] [PMC]

31.

Xu S, Gao X, Ma Y, Deng J, Xu S, Pan F. Association of methylation level and transcript level in TRAF5 gene with ankylosing spondylitis: a case-control study. Genes Immun. 2021;22:101–7. [DOI] [PubMed]

32.

Potter C, Eyre S, Cope A, Worthington J, Barton A. Investigation of association between the TRAF family genes and RA susceptibility. Ann Rheum Dis. 2007;66:1322–6. [DOI] [PubMed] [PMC]

33.

Xiang Q, Chen L, Fang J, Hou S, Wei L, Bai L, et al. TNF receptor-associated factor 5 gene confers genetic predisposition to acute anterior uveitis and pediatric uveitis. Arthritis Res Ther. 2013;15:R113. [DOI] [PubMed] [PMC]

34.

Xiang Q, Chen L, Hou S, Fang J, Zhou Y, Bai L, et al. TRAF5 and TRAF3IP2 gene polymorphisms are associated with behcet’s disease and vogt-koyanagi-harada syndrome: a case-control study. PLoS One. 2014;9:e84214. [DOI] [PubMed] [PMC]

35.

de Paiva CS, Trujillo-Vargas CM, Schaefer L, Yu Z, Britton RA, Pflugfelder SC. Differentially expressed gene pathways in the conjunctiva of sjögren syndrome keratoconjunctivitis sicca. Front Immunol. 2021;12:702755. [DOI] [PubMed] [PMC]

36.

Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity. 2018;49:725–39.e6. Erratum in: Immunity. 2020;52:203. [DOI] [PubMed] [PMC]

37.

Ota M, Nagafuchi Y, Hatano H, Ishigaki K, Terao C, Takeshima Y, et al. Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases. Cell. 2021;184:3006–21.e17. [DOI] [PubMed]

38.

So T, Ishii N. The TNF-TNFR family of co-signal molecules. In: Miyuki Azuma, Hideo Yagita, editors. Co-signal molecules in T Cell activation. Singapore: Adv Exp Med Biol; 2019. pp. 53–84. [DOI] [PubMed]

39.

Clouthier DL, Watts TH. Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection. Cytokine Growth Factor Rev. 2014;25:91–106. [DOI] [PubMed]

40.

Kanamaru F, Youngnak P, Hashiguchi M, Nishioka T, Takahashi T, Sakaguchi S, et al. Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25⁺ regulatory CD4⁺ T cells. J Immunol. 2004;172:7306–14. [DOI] [PubMed]

41.

Nocentini G, Ronchetti S, Petrillo MG, Riccardi C. Pharmacological modulation of GITRL/GITR system: therapeutic perspectives. Br J Pharmacol. 2012;165:2089–99. [DOI] [PubMed] [PMC]

42.

Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25⁺CD4⁺ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002;3:135–42. [DOI] [PubMed]

43.

Esparza EM, Lindsten T, Stockhausen JM, Arch RH. Tumor necrosis factor receptor (TNFR)-associated factor 5 is a critical intermediate of costimulatory signaling pathways triggered by gluccorticoid-induced TNFR in T cells*. J Biol Chem. 2006;281:8559–64. [DOI] [PubMed]

44.

Snell LM, McPherson AJ, Lin GH, Sakaguchi S, Pandolfi PP, Riccardi C, et al. CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection. J Immunol. 2010;185:7223–34. [DOI] [PubMed]

45.

Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018;131:39–48. [DOI] [PubMed]

46.

Bullock TN. Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer. Curr Opin Immunol. 2017;45:82–8. [DOI] [PubMed] [PMC]

47.

Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev. 2009;229:216–31. [DOI] [PubMed]

48.

Kraus ZJ, Haring JS, Bishop GA. TNF receptor-associated factor 5 is required for optimal T cell expansion and survival in response to infection. J Immunol. 2008;181:7800–9. [DOI] [PubMed] [PMC]

49.

Garlichs CD, Cicha I, Raaz D, Meyer L, Stumpf C, Klinghammer L, et al. CD40/CD154 system and pro-inflammatory cytokines in young healthy male smokers without additional risk factors for atherosclerosis. Inflamm Res. 2009;58:306–11. [DOI] [PubMed]

50.

Van Kooten C, Banchereau J. CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol. 1996;61:1–77. [DOI] [PubMed]

51.

Pullen SS, Miller HG, Everdeen DS, Dang TT, Crute JJ, Kehry MR. CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry. 1998;37:11836–45. [DOI] [PubMed]

52.

Leo E, Welsh K, Matsuzawa S, Zapata JM, Kitada S, Mitchell RS, et al. Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-κB and Jun N-terminal kinase activation*. J Biol Chem. 1999;274:22414–22. [DOI] [PubMed]

53.

Miyake K, Shibata T, Ohto U, Shimizu T, Saitoh SI, Fukui R, et al. Mechanisms controlling nucleic acid-sensing Toll-like receptors. Int Immunol. 2018;30:43–51. [DOI] [PubMed]

54.

Kawasaki T, Kawai T, Akira S. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol Rev. 2011;243:61–73. [DOI] [PubMed] [PMC]

55.

Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11:373–84. [DOI] [PubMed]

56.

Buchta CM, Bishop GA. TRAF5 negatively regulates TLR signaling in B lymphocytes. J Immunol. 2014;192:145–50. [DOI] [PubMed] [PMC]

57.

Kishimoto T. IL-6: from arthritis to CAR-T-cell therapy and COVID-19. Int Immunol. 2021;33:515–9. [DOI] [PubMed] [PMC]

58.

Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33:127–48. [DOI] [PubMed] [PMC]

59.

Nagashima H, Okuyama Y, Hayashi T, Ishii N, So T. TNFR-associated factors 2 and 5 differentially regulate the instructive IL-6 receptor signaling required for Th17 development. J Immunol. 2016;196:4082–9. [DOI] [PubMed]

60.

Kimura M, Nagashima H, Okuyama Y, Ishii N, So T. TRAF2 and TRAF5 associated with the signal transducing receptor gp130 limit IL-6-driven transphosphorylation of JAK1 through the inhibition of proximal JAK-JAK interaction. Int Immunol. 2018;30:291–9. [DOI] [PubMed]

61.

Serada S, Fujimoto M, Mihara M, Koike N, Ohsugi Y, Nomura S, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2008;105:9041–6. [DOI] [PubMed] [PMC]

62.

Kawamata S, Hori T, Imura A, Takaori-Kondo A, Uchiyama T. Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-κB activation*. J Biol Chem. 1998;273:5808–14. [DOI] [PubMed]

63.

Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev. 2009;229:173–91. [DOI] [PubMed] [PMC]

64.

Rincón M, Anguita J, Nakamura T, Fikrig E, Flavell RA. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4⁺ T cells. J Exp Med. 1997;185:461–70. [DOI] [PubMed] [PMC]

65.

Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector T_H17 and regulatory T cells. Nature. 2006;441:235–8. [DOI] [PubMed]

66.

Rose-John S. Therapeutic targeting of IL-6 trans-signaling. Cytokine. 2021;144:155577. [DOI] [PubMed]

67.

Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annu Rev Immunol. 2015;33:417–43. [DOI] [PubMed]

68.

Jones GW, Hill DG, Cardus A, Jones SA. IL-27: a double agent in the IL-6 family. Clin Exp Immunol. 2018;193:37–46. [DOI] [PubMed] [PMC]

69.

Peters A, Fowler KD, Chalmin F, Merkler D, Kuchroo VK, Pot C. IL-27 induces Th17 differentiation in the absence of STAT1 signaling. J Immunol. 2015;195:4144–53. [DOI] [PubMed] [PMC]

70.

Wilmes S, Jeffrey PA, Martinez-Fabregas J, Hafer M, Fyfe PK, Pohler E, et al. Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses. Elife. 2021;10:e66014. [DOI] [PubMed] [PMC]

71.

Chen Q, Ghilardi N, Wang H, Baker T, Xie MH, Gurney A, et al. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature. 2000;407:916–20. [DOI] [PubMed]

72.

Yoshida H, Hamano S, Senaldi G, Covey T, Faggioni R, Mu S, et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity. 2001;15:569–78. [DOI] [PubMed]